Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed Or Refractory Non-Hodgkin Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)WithdrawnNCT05929716
What this trial is testing

An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma

Who this might be right for
Large B-cell LymphomaB-cell Lymphoma
M.D. Anderson Cancer Center
Early research (Phase 1)Ended earlyNCT05515406
What this trial is testing

Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL

Who this might be right for
Lymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell
Ono Pharmaceutical Co., Ltd. 9
Testing effectiveness (Phase 2)WithdrawnNCT06005649
What this trial is testing

Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Who this might be right for
Non-hodgkin Lymphoma
Juventas Cell Therapy Ltd.
Testing effectiveness (Phase 2)Looking for participantsNCT06558604
What this trial is testing

Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma

Who this might be right for
Lymphoma, Mantle-Cell
The Lymphoma Academic Research Organisation 100
Early research (Phase 1)Study completedNCT05359211
What this trial is testing

NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

Who this might be right for
Recurrent Diffuse Large B-Cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Grade 3b Follicular Lymphoma+6 more
Fred Hutchinson Cancer Center 27
Early research (Phase 1)Study completedNCT01897012
What this trial is testing

Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas

Who this might be right for
MYC PositiveRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Burkitt Lymphoma+14 more
National Cancer Institute (NCI) 26
Testing effectiveness (Phase 2)Study completedNCT00967044
What this trial is testing

Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma

Who this might be right for
Lymphoma
M.D. Anderson Cancer Center 31
Early research (Phase 1)Active Not RecruitingNCT04684563
What this trial is testing

HuCART19-IL18 in CD19+ Cancers

Who this might be right for
Chronic Lymphocytic LeukemiaNon-hodgkin LymphomaAcute Lymphoblastic Leukemia
University of Pennsylvania 72
Not applicableStudy completedNCT02341781
What this trial is testing

Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment

Who this might be right for
Lymphoma, Mantle-Cell
Celgene 30
Testing effectiveness (Phase 2)Study completedNCT02164500
What this trial is testing

JAK-inhibition in Recurrent Classical Hodgkin Lymphoma

Who this might be right for
Recurrent Classical Hodgkin Lymphoma
University of Cologne 12
Early research (Phase 1)Ended earlyNCT03593109
What this trial is testing

A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma

Who this might be right for
Lymphoma, B-Cell
Second Affiliated Hospital of Xi'an Jiaotong University 1
Not applicableStudy completedNCT00049465
What this trial is testing

Standard Follow-up Compared With Extended Follow-up in Treating Patients Who Have Undergone Stem Cell Transplantation for Cancer

Who this might be right for
Cancer
Fred Hutchinson Cancer Center
Testing effectiveness (Phase 2)Study completedNCT00089011
What this trial is testing

Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia in Remission+171 more
Fred Hutchinson Cancer Center 150
Testing effectiveness (Phase 2)Study completedNCT02650999
What this trial is testing

Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas

Who this might be right for
CD19+ Diffuse Large B-cell LymphomasFollicular LymphomasMantle Cell Lymphomas
Abramson Cancer Center at Penn Medicine 12
Early research (Phase 1)Active Not RecruitingNCT02446236
What this trial is testing

Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma

Who this might be right for
Mantle Cell Lymphoma
Hackensack Meridian Health 27
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07162571
What this trial is testing

This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy for Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma.

Who this might be right for
Acute Lymphobkastic LeukemiaB Cell Lymphoma
Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology 17
Testing effectiveness (Phase 2)Active Not RecruitingNCT06300528
What this trial is testing

Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas

Who this might be right for
Relapsed or Refractory B-cell Non-Hodgkin LymphomaMantle Cell LymphomaMarginal Zone Lymphoma
University of Utah 1
Early research (Phase 1)Study completedNCT05665530
What this trial is testing

PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

Who this might be right for
Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Mantle Cell Lymphoma (MCL)+9 more
Prelude Therapeutics Incorporated 86
Testing effectiveness (Phase 2)Looking for participantsNCT06838832
What this trial is testing

Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL

Who this might be right for
Non-hodgkin Lymphoma,B Cell
Chinese PLA General Hospital 30
Early research (Phase 1)Study completedNCT00710528
What this trial is testing

Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Chronic Lymphocytic Leukemia (CLL)Lymphoma, Non-Hodgkin (NHL)Acute Myeloid Leukemia (AML)+1 more
Gilead Sciences 192
Next Page